144 related articles for article (PubMed ID: 21236235)
21. Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system.
Newes-Adeyi G; Greece J; Bozeman S; Walker DK; Lewis F; Gidudu J
Vaccine; 2012 Feb; 30(6):1050-5. PubMed ID: 22200501
[TBL] [Abstract][Full Text] [Related]
22. Serious adverse reactions should be further monitored after influenza A (H1N1) vaccination among children: postmarketing experience with 570,000 vaccinations between October 2009 and August 2010 in Guangzhou, China.
Fu C; Xu J; Tan H; Wang M
Pediatr Infect Dis J; 2011 Jul; 30(7):631-2. PubMed ID: 21673552
[No Abstract] [Full Text] [Related]
23. Anaphylaxis following H1N1 pandemic vaccines: safety data in perspective.
Tavares F; Delaigle A; Slavin D; Bauchau V; Fries L; Seifert H
Vaccine; 2011 Aug; 29(37):6402-7. PubMed ID: 21527305
[TBL] [Abstract][Full Text] [Related]
24. Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition.
Choe YJ; Cho H; Bae GR; Lee JK
Vaccine; 2011 Mar; 29(11):2066-70. PubMed ID: 21255684
[TBL] [Abstract][Full Text] [Related]
25. Annual report: surveillance of adverse events following immunisation in Australia, 2009.
Mahajan D; Roomiani I; Gold MS; Lawrence GL; McIntyre PB; Menzies RI
Commun Dis Intell Q Rep; 2010 Sep; 34(3):259-76. PubMed ID: 21090181
[TBL] [Abstract][Full Text] [Related]
26. Vaccines against influenza A (H1N1) pandemic.
Valdespino-Gomez JL; Garcia-Garcia L; de León-Rosales SP
Arch Med Res; 2009 Nov; 40(8):693-704. PubMed ID: 20304259
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
Lu CY; Shao PL; Chang LY; Huang YC; Chiu CH; Hsieh YC; Lin TY; Huang LM
Vaccine; 2010 Aug; 28(36):5864-70. PubMed ID: 20600484
[TBL] [Abstract][Full Text] [Related]
28. Positive attitudes of French general practitioners towards A/H1N1 influenza-pandemic vaccination: a missed opportunity to increase vaccination uptakes in the general public?
Schwarzinger M; Verger P; Guerville MA; Aubry C; Rolland S; Obadia Y; Moatti JP
Vaccine; 2010 Mar; 28(15):2743-8. PubMed ID: 20117271
[TBL] [Abstract][Full Text] [Related]
29. Relationship between intention of novel influenza A (H1N1) vaccination and vaccination coverage rate.
Kwon Y; Cho HY; Lee YK; Bae GR; Lee SG
Vaccine; 2010 Dec; 29(2):161-5. PubMed ID: 21055495
[TBL] [Abstract][Full Text] [Related]
30. [H1N1 influenza vaccines in Tunisia: efficiency and safety].
Chaabane A; Aouam K; Ben Fredj N; Toumi A; Braham D; A Boughattas N; Chakroun M
Therapie; 2011; 66(3):281-9. PubMed ID: 21819811
[TBL] [Abstract][Full Text] [Related]
31. Vaccination against pandemic influenza A/H1N1 among healthcare workers and reasons for refusing vaccination in Istanbul in last pandemic alert phase.
Torun SD; Torun F
Vaccine; 2010 Aug; 28(35):5703-10. PubMed ID: 20600497
[TBL] [Abstract][Full Text] [Related]
32. Annual report: surveillance of adverse events following immunisation in Australia, 2004.
Lawrence GL; Boyd I; McIntyre PB; Isaacs D
Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860
[TBL] [Abstract][Full Text] [Related]
33. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign.
Bone A; Guthmann JP; Nicolau J; Lévy-Bruhl D
Vaccine; 2010 Nov; 28(51):8157-61. PubMed ID: 20937310
[TBL] [Abstract][Full Text] [Related]
34. 2009 H1N1 influenza vaccines in pregnant women: the French Pharmacovigilance survey.
Lacroix I; Damase-Michel C; Kreft-Jais C; Castot A; Montastruc JL;
Vaccine; 2011 Feb; 29(7):1357-8. PubMed ID: 21185422
[No Abstract] [Full Text] [Related]
35. Adverse reaction of influenza A (H1N1) 2009 virus vaccination in pregnant women and its effect on newborns.
Lim SH; Lee JH; Kim BC; Jung SU; Park YB; Lee CS
Vaccine; 2010 Nov; 28(47):7455-6. PubMed ID: 20832495
[TBL] [Abstract][Full Text] [Related]
36. NSW annual report describing adverse events following immunisation, 2010.
Mahajan D; Campbell-Lloyd S; Cook J; Menzies RI
N S W Public Health Bull; 2011 Nov; 22(9-10):196-208. PubMed ID: 22060057
[TBL] [Abstract][Full Text] [Related]
37. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Nov; 58(44):1241-5. PubMed ID: 19910912
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
[TBL] [Abstract][Full Text] [Related]
40. Risk of fatal adverse events after H1N1 influenza vaccine: limitations of passive surveillance data.
McNeil MM; Broder KR; Vellozzi C; DeStefano F
Clin Infect Dis; 2010 Oct; 51(7):871-2; author reply 872-3. PubMed ID: 20809843
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
